NCT01558739View on ClinicalTrials.gov

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Primary Myelofibrosis (PMF)Post Polycythaemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Interventions
DRUG

INC424

Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.

Trial Locations (10)

CF14 4XN

Novartis Investigative Site, Cardiff

BH7 7DW

Novartis Investigative Site, Bournemouth

HU16 5JQ

Novartis Investigative Site, East Yorkshire

EH4 2XU

Novartis Investigative Site, Edinburgh

LE7 5WW

Novartis Investigative Site, Leicester

L7 8XP

Novartis Investigative Site, Liverpool

SE1 9RT

Novartis Investigative Site, London

W12 0HS

Novartis Investigative Site, London

M13 9NT

Novartis Investigative Site, Manchester

OX3 7LJ

Novartis Investigative Site, Oxford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY